These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25575144)

  • 41. Identification of priorities for medication safety in neonatal intensive care.
    Kunac DL; Reith DM
    Drug Saf; 2005; 28(3):251-61. PubMed ID: 15733029
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How to combine hygiene and radiation protection for radiopharmaceuticals preparation? Analysis in France and propositions.
    Biechlin ML; Léger S; Vial F; Desruet MD
    Nucl Med Commun; 2007 Nov; 28(11):876-8. PubMed ID: 17901772
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ocular toxicity in cataract surgery because of inaccurate preparation and erroneous use of 50mg/ml intracameral cefuroxime.
    Olavi P
    Acta Ophthalmol; 2012 Mar; 90(2):e153- 4. PubMed ID: 21470387
    [No Abstract]   [Full Text] [Related]  

  • 44. Identified safety risks with splitting and crushing oral medications.
    Paparella S
    J Emerg Nurs; 2010 Mar; 36(2):156-8. PubMed ID: 20211410
    [No Abstract]   [Full Text] [Related]  

  • 45. Promoting safe medication use in pediatric patients.
    Honey BL; Condren M
    Res Social Adm Pharm; 2010 Dec; 6(4):269-71. PubMed ID: 21111384
    [No Abstract]   [Full Text] [Related]  

  • 46. Use of a systematic risk analysis method to improve safety in the production of paediatric parenteral nutrition solutions.
    Bonnabry P; Cingria L; Sadeghipour F; Ing H; Fonzo-Christe C; Pfister RE
    Qual Saf Health Care; 2005 Apr; 14(2):93-8. PubMed ID: 15805453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting.
    Martinez M; Rathbone M; Burgess D; Huynh M
    J Control Release; 2008 Jul; 129(2):79-87. PubMed ID: 18514351
    [No Abstract]   [Full Text] [Related]  

  • 48. Stability of 10 mg/mL cefuroxime solution for intracameral injection in commonly used polypropylene syringes and new ready-to-use cyclic olefin copolymer sterile vials using the LC-UV stability-indicating method.
    Feutry F; Simon N; Genay S; Lannoy D; Barthélémy C; Décaudin B; Labalette P; Odou P
    Drug Dev Ind Pharm; 2016 Jan; 42(1):166-174. PubMed ID: 26006333
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs.
    Lam MS
    Pharmacotherapy; 2011 Feb; 31(2):164-92. PubMed ID: 21275495
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [ON THE PREPARATION OF UREA SOLUTION FOR INTRAVENOUS APPLICATION].
    MEINHARD J
    Pharm Prax; 1963; 43():147-8. PubMed ID: 14204154
    [No Abstract]   [Full Text] [Related]  

  • 51. [Remarks on the present-day status of the technology of injectable solutions and eye drops in the drug stores of the German Democratic Republic and proposals for its improvement].
    HORSCH W
    Pharm Prax; 1963; 2():21-3. PubMed ID: 13954997
    [No Abstract]   [Full Text] [Related]  

  • 52. Reducing patient harm with the use of opioid oral solutions.
    Grissinger M; Gaunt MJ
    Consult Pharm; 2011 Jun; 26(6):380-8. PubMed ID: 21628137
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of a standardized Intranet database of formulation records for nonsterile compounding, Part 2.
    Haile M; Anderson K; Evans A; Crawford A
    Int J Pharm Compd; 2012; 16(2):104-9. PubMed ID: 23050321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Preparations and stabilizations of syrups].
    SUSSIG B
    Boll Chim Farm; 1961 Mar; 100():188-96. PubMed ID: 13831296
    [No Abstract]   [Full Text] [Related]  

  • 55. [Requirements regarding compounded pharmaceutical preparation].
    Neef CK
    Ned Tijdschr Geneeskd; 2010; 154():A2032. PubMed ID: 20858313
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Compounding USP <797>: inspection, regulation, and oversight of sterile compounding pharmacies.
    Kastango ES
    JPEN J Parenter Enteral Nutr; 2012 Mar; 36(2 Suppl):38S-39S. PubMed ID: 22275322
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Compounding vs standardized commercial parenteral nutrition product: pros and cons.
    Gervasio J
    JPEN J Parenter Enteral Nutr; 2012 Mar; 36(2 Suppl):40S-41S. PubMed ID: 22301324
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Importance of an interruption-free environment for the safety of the patient while preparing and administering medications].
    Bermúdez Tamayo C; Celma Vicente M
    Enferm Clin; 2010; 20(5):315-6. PubMed ID: 20829086
    [No Abstract]   [Full Text] [Related]  

  • 59. Determination of risk for sterile preparations.
    ben-Horin SF; Rousso T
    Int J Pharm Compd; 2014; 18(1):30-4. PubMed ID: 24881337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Evaluation of administration errors of injectable drugs in neonatology].
    Cherif A; Sayadi M; Ben Hmida H; Ben Ameur K; Mestiri K
    Ann Pharm Fr; 2015 Nov; 73(6):461-70. PubMed ID: 25990871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.